Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REMS Need To Be More Easily Modified, Attorney Says; Prior Approval Supplements Too Cumbersome

Executive Summary

FDA could facilitate improvements to Risk Evaluation and Mitigation Strategies by giving companies some discretion to modify REMS elements, according to Hogan and Hartson partner Meredith Manning

You may also be interested in...



REMS Assessments Need Very Recent Data, FDA Draft Guidance Says

Sponsors conducting assessments of a product's Risk Evaluation and Mitigation Strategy will need to complete them within 60 days of collecting the last piece of data, according to a draft FDA guidance

REMS Assessments Need Very Recent Data, FDA Draft Guidance Says

Sponsors conducting assessments of a product's Risk Evaluation and Mitigation Strategy will need to complete them within 60 days of collecting the last piece of data, according to a draft FDA guidance

Will REMS Delay Generics? Revlimid Petition May Help Determine The Answer

Dr. Reddy’s asks FDA to spell out policy to assure that new Risk Evaluation and Mitigation Strategies will be used to block generics. Celgene’s refusal to make Revlimid available for bioequivalence study is at issue.

Related Content

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel